The Effect of Pioglitazon in Non-Alcoholig Fatty Liver Disease

Non -alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver test results in the U. S. A proportion of patients with NAFLD progress to advanced cirrhosis. Moreover، it is one of the clinical features of metabolic syndrome. This study was conducted in Shahid Sadoughi hospital in yazd، from September 2011 to march 2012. Eighty patients with NAFLD were enrolled in this study and then they were divided into two groups: case and control. The two groups underwent exercise and specific regiment، though in the case group subjects were also given 15 mg of pioglitazone twice a day. At the end of 24 weeks patients were reevaluated using ALT، BMI and sonography of liver. Sonography improvement occurred in both groups. Average of ALT improved in the case group and the difference in sonography between two groups was statistically meaningful.